Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 3754145, 12 pages
Research Article

The Anti-Inflammatory Effects of Invigorating Kidney and Supplementing Qi Chinese Herbal Formulae in Asthma Patients

1Institute of Integrated Traditional Chinese and Western Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
2Department of Integrated Traditional Chinese and Western Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
3Pneumology Department, Jiangsu Provincial Hospital of TCM, Nanjing 210029, China
4Pneumology Department, West China Hospital, Sichuan University, Chengdu 610041, China
5Pneumology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
6Pneumology Department, The First Affiliated Hospital of Henan University of TCM, Zhengzhou City, Henan Province 450008, China
7Department of Statistics, Fudan University, Shanghai 200032, China

Correspondence should be addressed to Jingcheng Dong; moc.621@4002gnodcj

Received 4 September 2016; Accepted 27 March 2017; Published 27 June 2017

Academic Editor: José L. Rios

Copyright © 2017 Lingwen Kong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The theories of Shen-reinforcement and Qi-supplementation are important in asthma treatment based on traditional Chinese medicine theories. Early studies suggested that Invigorating Kidney and Supplementing Qi herbal formulae, Bu Shen Fang Chuan (BSFC) and Bu Shen Yi Qi (BSYQ), conveyed promising results in asthma treatment. However, the efficacy and safety of the formulae need to be further investigated by a randomized double-blind clinical trial. Methods. 328 eligible patients were randomly sent to BSFC, BSYQ, and placebo group. The two formulae were received as add-on therapy. The primary endpoints were rate of asthma exacerbation and Hamilton Rating Scale for Depression (HAM-D) score. The secondary endpoints included HPA axis function and inflammatory cytokine production profile. All indexes were measured before and after treatment. Results. The primary endpoints were not improved in both groups; however, the depression levels of subgroup patients with HAM-D score > 5 were improved in BSFC group. HPA axis functions and inflammatory cytokines level were also improved by two formulae. The incidences of adverse events were similar among groups. Conclusions. The two formulae had multiple advantage effects on neuroendocrine-immune system. They are worth used as a replacement therapy in asthma. Trial Registration. This trial is registered with clinical trial number ChiCTR-PRC-09000529.